Additional Listing

RNS Number : 9695T
Oxford Biomedica PLC
10 October 2014

Additional Listing



Oxford, UK - 10 October 2014: Oxford BioMedica plc (LSE: OXB), ("OXB" or "the Group") a leading gene and cell therapy company, announces that, further to the announcement earlier this morning stating that OXB has signed further contracts with Novartis, application has been made to the UK Listing Authority and the London Stock Exchange for the 70,807,500 ordinary shares to trade on the London Stock Exchange and to be admitted to the Official List. These shares shall rank equally with the existing issued shares of OXB.


It is expected that admission will take place on 13 October 2014.





For further information, please contact:


Oxford BioMedica plc:

John Dawson, Chief Executive Officer

Tim Watts, Chief Financial Officer


Tel: +44 (0)1865 783 000


Financial PR enquiries:

Mary-Jane Elliott/Emma Thompson/Matthew Neal/Laura Thornton

Consilium Strategic Communications



Tel: +44 (0)20 3709 5700


Notes for editors


About Oxford BioMedica®

Oxford BioMedica plc (LSE: OXB) is a biopharmaceutical company developing innovative gene-based medicines and therapeutic vaccines that aim to improve the lives of patients with high unmet medical needs. The Group's technology platform includes a highly efficient LentiVector® gene delivery system, which has specific advantages for targeting diseases of the central nervous system and the eye; and a unique tumour antigen (5T4), which is an ideal target for anti-cancer therapy.  Through in-house and collaborative research, Oxford BioMedica has a broad range of partners and licensees including Sanofi, Pfizer, Novartis, GlaxoSmithKline, MolMed, Sigma-Aldrich, Biogen Idec, Emergent BioSolutions, ImaginAb and Immune Design Corp. Further information is available at and


This information is provided by RNS
The company news service from the London Stock Exchange